Alector, Inc. (ALEC) stock
ALECNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3069% below fair value
$2.54+0.09 (+3.67%)
Close on Nov 13, 2026Market cap $283.61MP/E 7.3Yield –
Alector ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Alector's ebitda for the twelve months ending Sep 30, 2026 was $39.24M. For fiscal 2025 it was -$150.29M. The highest annual figure on record is -$31.03M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$150.29M | – |
| FY2024 | Dec 31, 2024 | -$139.59M | – |
| FY2023 | Dec 31, 2023 | -$146.02M | – |
| FY2022 | Dec 31, 2022 | -$132.12M | – |
| FY2021 | Dec 31, 2021 | -$31.03M | – |
| FY2020 | Dec 31, 2020 | -$189.30M | – |
| FY2019 | Dec 31, 2019 | -$110.63M | – |
| FY2018 | Dec 31, 2018 | -$56.27M | – |
| FY2017 | Dec 31, 2017 | -$32.00M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $124.82M | – |
| Q2 FY2026 | Jun 30, 2026 | -$23.34M | – |
| Q1 FY2026 | Mar 31, 2026 | -$23.84M | – |
| Q4 FY2025 | Dec 31, 2025 | -$38.40M | – |
| Q3 FY2025 | Sep 30, 2025 | -$36.37M | – |
| Q2 FY2025 | Jun 30, 2025 | -$31.81M | – |
| Q1 FY2025 | Mar 31, 2025 | -$43.71M | – |
| Q4 FY2024 | Dec 31, 2024 | -$6.01M | – |
| Q3 FY2024 | Sep 30, 2024 | -$47.12M | – |
| Q2 FY2024 | Jun 30, 2024 | -$44.20M | – |
| Q1 FY2024 | Mar 31, 2024 | -$42.27M | – |
| Q4 FY2023 | Dec 31, 2023 | -$46.02M | – |
| Q3 FY2023 | Sep 30, 2023 | -$49.12M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.13M | -119.6% |
| Q1 FY2023 | Mar 31, 2023 | -$48.76M | – |
| Q4 FY2022 | Dec 31, 2022 | -$54.04M | – |
| Q3 FY2022 | Sep 30, 2022 | -$46.40M | -136.3% |
| Q2 FY2022 | Jun 30, 2022 | $10.86M | – |
| Q1 FY2022 | Mar 31, 2022 | -$42.53M | – |
| Q4 FY2021 | Dec 31, 2021 | -$54.14M | – |
| Q3 FY2021 | Sep 30, 2021 | $127.93M | – |
| Q2 FY2021 | Jun 30, 2021 | -$53.74M | – |
| Q1 FY2021 | Mar 31, 2021 | -$51.09M | – |
| Q4 FY2020 | Dec 31, 2020 | -$51.26M | – |
| Q3 FY2020 | Sep 30, 2020 | -$52.29M | – |
| Q2 FY2020 | Jun 30, 2020 | -$45.13M | – |
| Q1 FY2020 | Mar 31, 2020 | -$40.63M | – |
| Q4 FY2019 | Dec 31, 2019 | -$30.96M | – |
| Q3 FY2019 | Sep 30, 2019 | -$32.87M | – |
| Q2 FY2019 | Jun 30, 2019 | -$26.33M | – |
| Q1 FY2019 | Mar 31, 2019 | -$20.46M | – |
| Q4 FY2018 | Dec 31, 2018 | -$18.74M | – |
| Q3 FY2018 | Sep 30, 2018 | -$16.54M | – |
| Q2 FY2018 | Jun 30, 2018 | -$11.98M | – |
| Q1 FY2018 | Mar 31, 2018 | -$9.01M | – |
See a number that looks wrong?